Questions discussed in this category
What is your evaluation approach for RAI response? What cumulative dose do you use in practice for deciding a patient is RAI refractory?
Would you recommend aiming for the postmenopausal range as per the lab reference range or do you have a specific goal?
Or other therapy - e.g., tolvaptan? Free water restriction may hinder QOL. Salt tablets may raise levels more quickly but have risks of edema and hype...
Only the mCRPC population was included in the Fizazi et al. study, but the FDA approval is for prevention of skeletal related events from any solid tu...
Would you consider it for a patient with good PS but with limited metastatic disease? What dose fractionation would you prefer?
If so, what do you typically prescribe?
With studies showing non inferiority to zoledronic acid q 3 months in support of bone metastatic disease, would you consider extrapolating this data a...
If so, how often do you check these labs?
Do you look into their stage/risk to decide? Since patients can experience bone loss after stopping denosumab, how do you plan to discontinue?
Would you consider omitting treatment if small tumor and early stage? Or would you use tamoxifen?
Which agents would you select and for how long would you treat them?
For pts w/ eGFR between 30-60
Does the degree of resectability affect your management?
Recommendations in guidelines are discordant (ASCO vs NCCN vs UptoDate).
Is there concern for impaired healing? Do you pause therapy and for how long?
Should it be started at the initial diagnosis of bone mets?
What factors if any would influence your decision and what would your approach be?
Do you extrapolate the results of OPTIMIZE-2 and CALGB 70604 showing that an every 12 week dosing of zolendronic acid is noninferior to ever...
If a patient had a recurrence that was pathologically proven despite negative idodine scans, what imaging scans would you follow up with for surveilla...
20284206291673220370196811811819266125080301912814321169321586833721211134861402810874120781197388071129152589822899789638682704458886176606355819011093925839
Papers discussed in this category
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-04-10
Lancet, 2016 Mar 19
Eur. Urol.,
Lancet,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-07-20
Curr Treat Options Oncol, 2019 Mar 14
Leuk. Lymphoma, 2011 Feb 08
Cancer,
Cancer discovery, 2015-07
J Immunother Cancer,
J Clin Oncol, 2019 Sep 18
Blood, 2013-10-24
The Lancet. Oncology, 2011-08
The Lancet. Oncology, 2018-03
J Clin Oncol, 2022 Jan 18
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-12-10
Cancer Chemother Pharmacol, 2021 Mar 31
J Bone Miner Metab, 2020 Jul 12
The lancet. Diabetes & endocrinology, 2019 Aug 22
Clinics (Sao Paulo, Brazil), 2018 Dec 10
Metabolites, 2020 Jul 11
Protein & cell, 2014 Jul 12
Trends in biochemical sciences, 2016 Jan 05
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-05-10
The New England journal of medicine, 2018-07-12
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-05-10
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-04-10
Clinical breast cancer, 2023 Mar 28
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010 Jun 14
Annals of oncology : official journal of the European Society for Medical Oncology, 2022 Mar 14
Journal of the Endocrine Society, 2022 Dec 02
Diagnostics (Basel, Switzerland), 2021 Apr 20